Is the Novo partnership with Hims & Hers confirmed?

Bloomberg reports the companies resolved their dispute and will sell obesity drugs together, with a formal announcement expected Monday. Until official details post, treat it as highly likely but not closed. Watch for terms on product scope, timelines, and supply. Those specifics will guide revenue potential and execution risk.

How could Wegovy sales impact Hims’ financials?

Branded GLP-1s can lift conversion, trust, and retention versus compounded options. That can raise revenue per user and improve cohort lifetime value. Margins may benefit if customer acquisition spends scale better. The impact will depend on supply reliability, payer coverage, and adherence. These variables will shape the trajectory for hims stock.

What do valuation and analyst views look like now?

Hims trades near 30.9 times TTM earnings and about 1.46 times sales. Analyst views skew cautious, with 3 Buys, 15 Holds, and 9 Sells. If branded GLP-1 uptake is smooth and margins hold, sentiment could improve. Weak supply, pricing pressure, or higher churn could cap multiple expansion.

What events should investors watch next?

First, the official partnership announcement and onboarding timelines. Second, subscription metrics for GLP-1 programs, including refills and adherence. Third, any payer or regulatory updates. Finally, earnings on May 4, 2026, where management may detail guidance and GLP-1 conversion trends that can influence near-term stock direction.

Global Market Insights

HIMS Stock Today, March 07: Novo Deal Paves Way for Wegovy Sales

ByHuzaifa Zahoor March 8, 2026March 8, 2026

News of a Hims Novo partnership is moving focus to hims stock today. Bloomberg reports Novo Nordisk will sell Wegovy and other GLP-1 obesity drugs through Hims & Hers, with a formal announcement expected Monday. For investors, access to branded supply could speed revenue and lower regulatory risk tied to compounded semaglutide. Shares of HIMS trade near $15.74, with a P/E around 30.9. We outline the upside, risks, and what to watch next for hims stock.